Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1 Tamoxifen-resistant cells develop individual as well as common drug sensitivities and co-resistances. Sensitizing and desensitizing drugs, drug target classes, specific target genes and as well as affected cell lines are listed

From: Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer

Sensitivity towards Drug target class Specific target gene Observed in cell line
Navitoclax, Obatoclax BCL-family BCL2L1 T-47D Tam1
BAD
RAF265, Ponatinib RAF-family RAF1 T-47D Tam1
Dasatinib, KX2-391 SRC/ABL ABL1 T-47D Tam1 & Tam2
SRC
VX-11E MAPK1 MAPK1 T-47D Tam2, BT-474 Tam2, ZR-75-1 Tam2
Gefitinib, Ibrutinib, Neratinib, Nintedanib HER2/EGFR ERBB2 BT-474 Tam1 & Tam2
ERBB4
ERBB3
Vinblastine Tubulins TUBA1A T-47D Tam2
TUBA4A
TUBA1C
TUBB6
PF-3845 FAAH FAAH ZR-75-1 Tam2
Bortezomib PSMB-family PSMB5 ZR-75-1 Tam2
Resistance towards Drug target class Specific target gene Observed in cell line
YM155 BIRC5 BIRC5 T-47D Tam1 & Tam2, MCF-7 Tam1, BT-474 & Tam2
Quisinostat, Panobinostat HDACs HDAC1 T-47D Tam2, MCF-7 Tam1
HDAC6
Docetaxel, Paclitaxel Tubulins TUBA1C BT-474 Tam2
TUBB2A
TUBB3
TUBB
TUBB4B
TUBB6
Temsirolimus, Everolimus, Ridaforolimus, INK128, Sirolimus, AZD8055, Dactolisib mTOR mTOR MCF-7 Tam1